{
    "clinical_study": {
        "@rank": "87432", 
        "arm_group": {
            "arm_group_label": "SyB C-1101", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate tolerability when SyB C-1101 is orally\n      administered twice daily for 14 consecutive days to the patients with recurrent/relapsed or\n      refractory myelodysplastic syndrome, to determine the dose-limiting toxicity and maximum\n      tolerated dose, and to estimate the recommended dose for phase II studies. Pharmacokinetics\n      and antitumor effects will also be investigated."
        }, 
        "brief_title": "Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients must satisfy the following conditions listed below:\n\n          1. Patients who have been histologically documented or cytologically confirmed with\n             myelodysplastic syndrome (MDS), and who have been found to meet any of the following\n             criteria on the basis of the WHO classification or French-American-British (FAB)\n             classification.\n\n               -  Refractory Anemia (RA)* (< 5% myeloblasts, < 15% ringed sideroblasts)\n\n               -  RA with Ring Sideroblasts (RARS)* (< 5% myeloblasts, \u2265 15% ringed sideroblasts)\n\n               -  RA with Excess of Blasts-1(RAEB-1)(5% to 9% myeloblasts)\n\n               -  RAEB-2 (10% to 19% myeloblasts)\n\n               -  RAEB-t (20% to 29% myeloblasts or < 25,000/mm3 peripheral leukocytes)\n\n               -  Chronic myelomonocytic leukemia (CMML) (10% to 19% myeloblasts, \u2265 1,000/mm3\n                  peripheral monocytes, < 13,000/mm3 leukocytes) * RA and RARS patients should\n                  have 2 or more units of erythrocyte transfusion within 8 weeks.\n\n          2. Patients with a low value in at least one blood cell lineage (having at least one of\n             the following cytopenias).\n\n               -  Neutrophils : < 1,800/mm3\n\n               -  Platelets : < 100,000/mm3\n\n               -  Hemoglobin : < 10 g/dL\n\n          3. Patients with a previous history of chemotherapy (including immunosuppressive\n             therapy, anabolic steroid and lenalidomide) for the target disease who meet any of\n             the following criteria.\n\n               -  Patients who have not achieved complete remission, partial remission, or\n                  hematologic improvement.*\n\n               -  Patients with recurrence/relapse after complete remission, partial remission, or\n                  hematologic improvement.*\n\n               -  Patients with intolerability that has led to discontinuation of treatment\n                  because of the development of liver dysfunction, kidney dysfunction, etc., after\n                  the start of treatment. *Proximate therapeutic efficacy judged under IWG 2006\n                  criteria.\n\n          4. For the patients who have received chemotherapy such as immunosuppressive therapy,\n             anabolic steroid and lenalidomide, the patients should have not been treated for four\n             weeks or longer after the end of the previous therapy and be judged to have no\n             residual effects (antitumor effects) from the previous therapy.\n\n          5. Patients who can be expected to survive at least three months or longer.\n\n          6. Patients at least 20 years old (when informed consent is obtained).\n\n          7. Patients who have score of 0 to 2 in The Eastern Cooperative Oncology Group (ECOG)\n             Performance Status (PS).\n\n          8. Patients with adequate function in major organs (heart, lungs, liver, kidneys, etc.).\n\n               -  Aspartate aminotransferase (AST) : no greater than 3.0 times the upper boundary\n                  of the reference range at each institution\n\n               -  Alanine aminotransferase (ALT) : no greater than 3.0 times the upper boundary of\n                  the reference range at each institution\n\n               -  Total bilirubin: no more than 1.5 times the upper boundary of the reference\n                  range at each institution\n\n               -  Serum creatinine: no more than 1.5 times the upper boundary of the reference\n                  range at each institution\n\n               -  ECG: no abnormal findings requiring treatment\n\n               -  Echocardiography: no abnormal findings requiring treatment\n\n          9. Patients who personally signed an informed consent document for participation in this\n             study.\n\n        Exclusion Criteria:\n\n        Patients who satisfy any of the following conditions will not be enrolled in the study.\n\n          1. Patients with anemia caused by factors other than MDS (hemolytic anemia,\n             gastrointestinal (GI) bleeding, etc.)\n\n          2. Patients with hypoplasia MDS (< 10% osteocyte density)\n\n          3. Patients who have undergone treatment for an active malignant tumor within the past\n             year (except basal cell or squamous cell skin cancer, or primary squamous cell\n             carcinoma of the cervix or noninvasive breast cancer).\n\n          4. Patients who have been administered a cytokine preparation such as G-CSF\n             (granulocyte-colony stimulating factor), erythropoietin, etc. within 14 days of tests\n             for enrollment of the study.\n\n          5. Patients with obvious infectious diseases (including viral infections).\n\n          6. Patients with serious complications (liver failure, renal failure, etc.).\n\n          7. Patients with a complication or previous history of serious heart disease (myocardial\n             infarction, ischemic heart disease, etc.) within the past two years before\n             enrollment, and with cardiac arrhythmia requiring treatment.\n\n          8. Patients with a serious gastrointestinal condition (severe or significant\n             nausea/vomiting, diarrhea, etc.)\n\n          9. Patients who are positive for the Hepatitis B surface antigen (HBs) antigen or HIV\n             antibodies.\n\n         10. Patients with serious bleeding tendencies (disseminated intravascular coagulation\n             (DIC), internal hemorrhage, etc.).\n\n         11. Ascites or pleural fluid requiring active medical management including paracentesis,\n             or hyponatremia (defined as serum sodium value of < 130 mEq/L).\n\n         12. Patients who have been administered a drug in a clinical trial or an unapproved drug\n             within three months before enrollment.\n\n         13. Patients who have previously treated with the test drug (rigosertib sodium).\n\n         14. Patients with known allergy to polyethylene glycol or gelatin capsules.\n\n         15. Patients with an addiction to a legal or illegal drug, or with alcohol dependency.\n\n         16. Patients who are pregnant or may become pregnant, or lactating mothers.\n\n         17. Patients who have not consented to the following contraceptive measures. Patients\n             will avoid sexual intercourse with sexual partners or should use the following\n             contraceptive methods in these time periods: for male patients during the\n             administration period of the trial and for six months after the end of\n             administration; female patients during the administration period of the trial, and\n             until a second menstrual period is confirmed after the end of administration (or in\n             the case of female patients with no menstrual period, for two months after the end of\n             administration).\n\n               -  Male patients: Patients will always use a condom. For effective contraception,\n                  it is recommended that the female partner also use the contraceptive methods for\n                  female patients.\n\n               -  Female patients: Female patients who may become pregnant should use one or more\n                  types of the following contraceptive methods. In addition, the male partner will\n                  always use a condom. Oral contraceptive (birth control pills) , Intrauterine\n                  device (IUD) , Tubal ligation\n\n         18. Other patients judged to be unsuitable by an investigator or sub-investigators."
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014051", 
            "org_study_id": "2012002"
        }, 
        "intervention": {
            "arm_group_label": "SyB C-1101", 
            "description": "SyB C-1101\uff08rigosertib sodium\uff09 will be administered to two cohorts at either 280 mg/day or 560 mg/day.\nThe dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.\nThe study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle.", 
            "intervention_name": "SyB C-1101", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "December 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya", 
                        "country": "Japan", 
                        "state": "Aichi"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Isehara", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai", 
                        "country": "Japan", 
                        "state": "Miyagi"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto", 
                        "country": "Japan"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome", 
        "overall_contact": {
            "email": "hmatsuoka.svp@symbiopharma.com", 
            "last_name": "Hiroaki Matsuoka", 
            "phone": "+81-3-5472-1127"
        }, 
        "overall_official": {
            "affiliation": "SymBio Pharmaceuticals", 
            "last_name": "Katsuhisa Goto", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "type, frequency, severity, reversibility", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014051"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "clinical laboratory test results and abnormal clinical laboratory test results throughout the study", 
                "measure": "Changes in clinical laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and up to 18 weeks"
            }, 
            {
                "description": "Total efficacy in hematologic remission ratio [ratio of patients scored as complete remission (CR), partial remission (PR), or marrow CR according to IWG 2006 criteria]. Definitions of CR, PR, marrow CR are shown below.\nCR:Bone marrow: \u22645% myeloblasts with normal maturation of 3 cell lines (persistent dysplasia should be noted) Peripheral blood: All of the following conditions are met when blood transfusion therapy and cytokine therapy are ineffective. Hb \u226511 g/dL, platelets \u2265100,000/\u00b5L, Neutrophils \u22651000/\u00b5L, blasts 0%.\nPR:All CR criteria met, except following:Bone marrow: Blasts decreased by \u226450% compared to base-line but still >5% (peripheral blood findings must be normal same as CR).\nmarrow CR: Bone marrow: \u22645% blasts and decreased by \u226550%, but peripheral blood findings do not meet criteria for CR (Hematological improvement: Hematologic improvement responses should be noted, such as: Marrow CR with Hematologic improvement-erythroid, marrow CR without Hematologic improvement.)", 
                "measure": "Total efficacy in hematologic remission ratio according to Clinical application and proposal for modification of the International Working Group response criteria in myelodysplasia (IWG) 2006 criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 weeks"
            }, 
            {
                "description": "Total efficacy in hematologic improvement ratio (ratio of patients scored as hematologically improved \"erythrocyte lineage, platelet lineage, or neutrophil lineage\") according to IWG 2006 criteria. Definition of \"hematologic improvement\" is shown below:\nHematologic improvement-erythroid (base-line <11 g/dL):\n\u22651.5 g/dL increase in Hb. Decrease of \u22654 units/8 weeks in blood transfusion volume compared to base-line (only cases of blood transfusion given for Hgb \u22649 g/dL will be assessed based on transfusion volume)\nHematologic improvement-platelet (base-line <100,000/\u00b5L):\nCases with \u226520,000/\u00b5L: \u226530,000/\u00b5L increase compared to base-line. Cases with <20,000/\u00b5L: Increase to \u226520,000/\u00b5L, with at least a 2-fold increase in base-line level\nHematologic improvement-neutrophil (base-line <1,000/\u00b5L):\nAt least a 2-fold increase in base-line level, to \u2265500/\u00b5L", 
                "measure": "Total efficacy in hematologic improvement ratio  according to IWG 2006 criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 weeks"
            }, 
            {
                "description": "Maximum concentration in plasma (Cmax), Time to maximum plasma concentration (tmax), Area under the plasma concentration curve (AUC), Elimination half-life (t1/2), and Urinary excretion rate.", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "On Day 1, Day 8 and Day14"
            }
        ], 
        "source": "SymBio Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SymBio Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}